CASRAI Dictionary

Author: MCP Service

  • Electronic Research Administration: What to Evaluate in 2026

    What electronic research administration actually means

    Electronic research administration (commonly abbreviated ERA, and sometimes called eRA) refers to the digital systems and workflows that universities, hospitals, and research institutes use to manage the full lifecycle of sponsored research — from identifying a funding opportunity through proposal submission, award negotiation, compliance monitoring, and financial closeout. The term covers both the specific federal touchpoints, such as the US National Institutes of Health’s eRA Commons and ASSIST systems, and the broader category of institutional research administration software that sits between researchers, sponsors, and finance offices.

    Most research-intensive institutions no longer run these processes on spreadsheets and shared drives. They run them through a dedicated electronic research administration system, or a stack of interoperable modules, because sponsors themselves have moved to electronic submission. Grants.gov, the UK’s UKRI Funding Service, and Horizon Europe’s portal all require electronic workflows on the sponsor side; institutional ERA platforms exist largely to feed proposals into — and pull award data back out of — those sponsor systems without duplicate manual entry.

    Core modules: pre-award, post-award, compliance, effort reporting

    Despite different vendor branding, mature ERA platforms converge on a broadly consistent set of functional modules. The table below summarises what each typically covers and where it interacts with external systems.

    Module What it typically covers External touchpoints
    Pre-award Funding-opportunity discovery, proposal development, budget building, internal sign-off routing Grants.gov, UKRI Funding Service, sponsor portals
    Post-award Award setup, budget tracking, subaward management, financial reporting to sponsors Institutional finance/ERP systems
    Compliance Conflict-of-interest disclosure, IRB and IACUC protocol tracking, export-control screening, foreign-component disclosure Institutional COI registers, ORCID iDs
    Effort reporting Certifying personnel time charged to sponsored awards against actual effort HR/payroll systems, 2 CFR 200.430
    Analytics/reporting Portfolio dashboards, proposal-to-award conversion, audit-readiness reporting Institutional data warehouses

    Few institutions run all five modules from a single vendor. Chief research officers most often report assembling a stack — a proposal-routing tool from one vendor, a dedicated compliance or effort-reporting module from another — connected through system-to-system integrations rather than buying one suite outright. That reality should shape how any evaluation is scoped: interoperability matters as much as feature breadth.

    Why Uniform Guidance and audit scrutiny are reshaping ERA requirements

    US institutions receiving federal research funding operate under the Office of Management and Budget’s Uniform Guidance (2 CFR Part 200). OMB’s 2024 revisions to that guidance — effective for federal awards issued on or after 1 October 2024 — raised the Single Audit expenditure threshold from $750,000 to $1,000,000 and increased the de minimis indirect cost rate available to institutions without a negotiated rate from 10% to 15%. Both changes alter what an ERA system needs to track and report, and by when.

    • A higher Single Audit threshold shifts more institutions toward risk-based, targeted monitoring rather than a full annual audit — which means ERA compliance modules need to surface exception-based flags, not just generate end-of-year reports.
    • The revised de minimis rate changes how budget and indirect-cost calculations should populate proposal templates by default.
    • Effort reporting remains a perennial audit focus area under 2 CFR 200.430, and reviewers increasingly expect systems to certify effort against documented time-and-attendance data rather than after-the-fact estimates.

    Outside the US, UK and EU institutions face parallel pressure: UKRI’s move to its unified Funding Service and Horizon Europe’s stricter foreign-funding disclosure rules both push institutions toward systems that can evidence compliance on demand rather than reconstruct it retrospectively. An ERA platform selected in 2026 needs to be configurable against a moving regulatory baseline, not just the rules in force at implementation.

    A buyer’s framework: what to evaluate before selecting a platform

    Selection committees — typically a chief research officer, sponsored-programs staff, IT, and finance — should evaluate candidate platforms against criteria that go beyond a feature checklist:

    • Configuration versus customisation. Configurable, vendor-supported systems require less internal IT investment but less bespoke fit; heavily customised systems demand ongoing internal development capacity and are harder to keep current when a vendor ships updates.
    • Audit and compliance readiness. Ask vendors to demonstrate exception-based compliance flagging (COI, effort variance, subrecipient risk), not only static reports generated after the fact.
    • Interoperability. Confirm documented integrations with sponsor systems (Grants.gov, eRA Commons, UKRI Funding Service), identity systems (ORCID), and the institution’s own ERP/HR platforms.
    • Total cost of ownership. Homegrown and heavily customised builds frequently carry hidden maintenance costs beyond the initial development estimate; request a multi-year cost breakdown, not just licence price.
    • Vendor stability and support. Research administration software has consolidated significantly through vendor mergers and rebrands over the past decade; ask about implementation timelines, support SLAs, and product roadmap commitments in writing.

    What is electronic research administration?

    Electronic research administration is the use of digital systems to manage the sponsored-research lifecycle — proposal development, award setup, compliance tracking, and financial reporting — in place of paper-based processes. It replaces manual routing and signatures with system-based workflows that connect directly to sponsor submission portals such as Grants.gov.

    What does a research administrator do?

    A research administrator develops and oversees research proposals, awards, and financial transactions on behalf of an institution and its principal investigators. Core duties include budget development, compliance monitoring, and maintaining records that satisfy both institutional policy and sponsor requirements — increasingly through an electronic research administration system rather than paper files.

    What is the difference between eRA and NIH?

    eRA (the NIH’s Electronic Research Administration platform, including eRA Commons and ASSIST) is the online interface through which grant applicants, grantees, and NIH staff exchange administrative information about federal grants. NIH is the funding agency itself; eRA is one agency’s specific electronic system, not a synonym for the broader ERA software category institutions purchase.

    What are ERA systems?

    ERA systems are institutional software platforms — commercial or, less commonly, homegrown — that manage sponsored-research workflows end-to-end. They typically combine pre-award, post-award, compliance, and effort-reporting modules, and connect to external sponsor and identity systems such as Grants.gov and ORCID.

    Implications for institutions, funders, and publishers

    For institutions, the practical implication of tighter Uniform Guidance thresholds and rising audit scrutiny is that ERA selection is no longer purely an IT or finance-office decision — it is a compliance-risk decision that belongs on the chief research officer’s desk. Systems chosen primarily on price or user-interface polish, without a documented compliance-flagging capability, risk becoming an audit liability rather than an efficiency gain.

    For funders and publishers, the growth of ERA adoption strengthens the case for standardised metadata at the point of proposal and award creation — identifiers such as ORCID iDs and the Research Organization Registry (ROR) reduce downstream reconciliation work when award data eventually needs to map to publications, contributor roles, and institutional affiliations. Professional bodies including NCURA, ARMA, EARMA, and INORMS have each published guidance and community benchmarking on ERA adoption, reflecting how central this tooling decision has become to the research-administration profession globally.

    Outlook: ERA selection as a 2026 strategic priority

    The direction of travel is clear: sponsors are tightening disclosure and audit expectations at the same time as institutions face budget pressure to do more with fewer administrative staff. An ERA platform that cannot demonstrate compliance readiness against a moving regulatory baseline — and that cannot interoperate cleanly with sponsor and identity systems — will struggle to justify its cost within two to three budget cycles. Institutions evaluating platforms in 2026 should treat the selection process as an ongoing compliance investment rather than a one-off procurement exercise, revisiting vendor roadmaps annually against the next round of Uniform Guidance and sponsor-portal changes.

    Institutions building out their research administration function more broadly can also consult CASRAI’s research administration resources and the CASRAI Dictionary for grounded definitions of the compliance and reporting terms that ERA systems are built to track.

  • Pre-Award vs Post-Award Research Administration: Where Compliance Risk Concentrates

    Every sponsored-research office eventually asks the same operational question: where, exactly, does an audit finding get born? Pre-award research administration and post-award research administration are often treated as a single continuous job description, but they carry very different compliance profiles. Under the Office of Management and Budget’s Uniform Guidance (2 CFR 200), the two phases are governed by overlapping but distinct subparts, and institutions that blur the boundary tend to discover the gap only when a federal auditor draws attention to it.

    This guide separates the two functions, maps the specific 2 CFR 200 provisions most associated with audit findings, and flags what changed when OMB’s most recent revision took effect.

    Pre-award vs post-award: where the line falls

    Pre-award activity covers everything that happens before an institution accepts a sponsor’s terms. It is proposal-facing rather than transaction-facing, and its compliance burden is concentrated in representations made to the sponsor rather than in ongoing financial stewardship.

    • Identifying and matching funding opportunities to investigator plans
    • Budget justification and application of institutional/federal indirect cost rates
    • Compliance screening — conflict-of-interest disclosure, human/animal subject clearances, export control review
    • Internal routing, sign-off, and proposal submission
    • Award negotiation and formal acceptance of terms

    Post-award administration begins the moment an award account is set up and runs through closeout. This is where the volume and complexity of federal financial transactions live, which is also why post-award research administration generates a disproportionate share of Single Audit findings.

    • Award and general ledger account setup
    • Ongoing financial compliance monitoring — allowability, allocability, and reasonableness of costs
    • Effort certification and personnel cost justification
    • Subrecipient monitoring on any pass-through funds
    • Interim and final financial and progress reporting
    • Project closeout, equipment disposition, and unused-funds reconciliation

    Bodies such as research administration professional associations — ARMA in the UK, NCURA in the US, and EARMA across Europe — increasingly teach pre-award and post-award as a connected lifecycle rather than two silos, precisely because handoff gaps between the two are where compliance exposure accumulates.

    The compliance risk heatmap

    Not every task carries equal audit exposure. Mapping common research-administration tasks against the Uniform Guidance provisions auditors cite most often produces a practical heatmap for prioritising internal review effort.

    Phase Task Governing 2 CFR 200 provision Typical audit-finding risk
    Pre-award Budget development / indirect cost application Subpart E — Cost Principles Low–Medium
    Pre-award Conflict-of-interest and subject-protection clearance §200.112, institutional policy Medium
    Post-award Procurement of goods/services on federal funds §§200.317–200.327 High
    Post-award Subrecipient monitoring §§200.331–200.333 High
    Post-award Internal controls over federal expenditure §200.303 High
    Post-award Effort certification / salary charging Subpart E, Compensation Medium–High
    Post-award Financial and progress reporting timeliness §§200.328–200.329 Medium
    Post-award Closeout and equipment disposition §§200.344–200.345 Low–Medium

    The pattern is consistent across institutional Single Audits: pre-award weaknesses tend to surface as proposal-accuracy or disclosure gaps, while post-award weaknesses — inadequate subrecipient monitoring, undocumented internal controls, and procurement shortcuts — account for the majority of significant deficiencies reported to cognizant agencies. That imbalance is exactly why post-award teams typically carry larger headcount relative to transaction volume, even though pre-award work is more visible to investigators.

    The Uniform Guidance is changing

    OMB’s most recent revision to 2 CFR 200 took effect for federal awards issued on or after 1 October 2024, and it directly reshapes several of the risk areas above. Institutions still operating on pre-2024 assumptions are the ones most likely to generate findings against the revised text.

    • The Single Audit expenditure threshold rose from $750,000 to $1,000,000, removing some smaller institutions from mandatory audit scope but concentrating audit attention on larger, more complex programmes.
    • The de minimis indirect cost rate available to entities without a negotiated rate agreement rose from 10% to 15% of modified total direct costs.
    • The equipment and capital-asset capitalisation threshold rose from $5,000 to $10,000, changing what must be separately tracked and reported at closeout.

    Further clarifying guidance and agency-specific implementation notes continue to be issued as sponsors align their own policy manuals with the revised text, which means the compliance target for both pre-award and post-award teams is still moving. Research offices that update proposal templates and account-setup checklists only once, at the point of the original 2024 change, risk drifting out of alignment as agencies finish rolling out their own interpretations.

    Common questions on pre-award and post-award risk

    What is pre-award research administration?

    Pre-award research administration is the set of institutional functions that support a project from funding search through award acceptance — matching opportunities, building compliant budgets, screening for conflicts of interest, and routing proposals for internal sign-off before submission to a sponsor.

    What is the pre-award process?

    The pre-award process runs from identifying a funding opportunity through formal award acceptance. It typically includes proposal development, budget justification, internal institutional review, submission to the sponsor, and negotiation of final award terms before the account is established.

    What is a pre-award?

    A pre-award refers to the preparatory documentation and approvals — intent-to-apply forms, budget justifications, compliance certifications — completed before a sponsor formally commits funding. These records establish the institutional and regulatory basis the eventual award will be managed against.

    What skills do you need to be a research administrator?

    Research administrators need working knowledge of sponsor and federal regulations (including the Uniform Guidance), budget and financial analysis skills, attention to procedural detail, and the ability to translate technical compliance requirements into plain guidance for investigators.

    Implications for research offices

    The practical takeaway is not that pre-award compliance is unimportant — a flawed conflict-of-interest disclosure or an unallowable cost baked into a budget justification can still trigger scrutiny. The takeaway is that sponsored research administration teams should weight their internal review and training investment toward where findings actually concentrate: procurement, subrecipient monitoring, and documented internal controls in the post-award phase.

    Institutions that separate “grant administration” from “grant management” organisationally sometimes reproduce the same handoff risk internally — pre-award teams hand a fully compliant proposal to post-award teams who inherit responsibility for terms they did not negotiate. A shared risk register, reviewed jointly across both functions at account setup, closes that gap more reliably than siloed checklists. Institutional glossaries and shared reference material — see CASRAI’s research administration glossary — help standardise the terminology both teams use when escalating a compliance question.

    Looking ahead

    As OMB continues to refine implementation guidance around the 2024 Uniform Guidance revision, the boundary between pre-award and post-award compliance work will keep shifting rather than settling. Research offices that treat the two phases as a connected risk chain — rather than a handoff between departments — will be better positioned to absorb the next round of regulatory change without a corresponding spike in audit findings.

  • Grant Administration vs Grant Management: A Research-Office Guide

    A sponsored programmes office in a university, hospital trust, or research institute rarely has the luxury of clean job titles. Staff are asked to do “grants work” without anyone specifying which of two genuinely different functions they mean. Grant administration vs grant management is not a semantic quibble — it maps onto two distinct phases of the funding lifecycle, with different skills, different risk profiles, and different reporting lines. Getting the distinction right affects how research offices staff themselves, how they onboard new starters, and how they explain their own structure to auditors and funders.

    This explainer sets out the practical difference, shows where each function sits against the pre-award/post-award lifecycle, and answers the questions research administrators most commonly search for when trying to draw the line.

    What is grant administration?

    Grant administration is the compliance-facing, largely post-award function. It exists to make sure that once money has been awarded, it is spent, tracked, and reported exactly as the funder’s terms and conditions require. Grant administrators are the people who keep an award audit-ready from the moment funds land to the moment the final financial report is submitted.

    Typical grant administration duties include:

    • Setting up the award in the institution’s financial system and reconciling it against the signed agreement
    • Monitoring budget lines, allowable costs, and cost transfers against the approved grant budget
    • Tracking effort reporting, cost-sharing commitments, and indirect cost (overhead) recovery
    • Preparing and submitting financial and progress reports on the funder’s schedule
    • Managing award amendments, no-cost extensions, and close-out procedures

    In US institutions this work is typically anchored to the Uniform Guidance (2 CFR 200) and individual agency terms from bodies such as NIH and NSF. In the UK, the equivalent compliance backbone runs through UKRI’s grant terms and conditions, institutional TRAC (Transparent Approach to Costing) returns, and Research England reporting requirements. The regulatory vocabulary differs by jurisdiction; the underlying function — disciplined, rules-bound post-award stewardship — does not.

    What is grant management?

    Grant management is the broader, strategic function that spans the entire lifecycle: identifying funding opportunities, shaping competitive proposals, and — once an award is won — overseeing whether the funded work is actually achieving its research and institutional objectives. Where administration asks “are we compliant?”, management asks “are we winning the right grants, and are they delivering what we promised?”

    Typical grant management responsibilities include:

    • Scanning funder calls and matching them to institutional and departmental research priorities
    • Supporting principal investigators with proposal development, budget justification, and costing
    • Building and maintaining relationships with programme officers and funder liaison staff
    • Monitoring project performance against milestones, outputs, and outcomes — not just spend
    • Feeding lessons from completed awards back into future bid strategy

    A grant manager’s remit therefore extends well beyond a single award. Many sponsored programmes offices structure this as a “grants management cycle” — pre-award identification and proposal support, award negotiation, post-award delivery oversight, and closeout evaluation that feeds the next cycle.

    Pre-award vs post-award: mapping the responsibilities

    The cleanest way to separate the two functions is against the pre-award/post-award split that most research administration offices already use to structure their teams. Grant management is lifecycle-wide; grant administration is concentrated in — though not exclusively confined to — the post-award phase.

    Dimension Grant administration Grant management
    Primary lifecycle stage Post-award Pre-award through closeout
    Core question Are we compliant with the award terms? Are we funding — and delivering — the right work?
    Typical tasks Budget monitoring, cost transfers, financial reporting, audit readiness Opportunity scanning, proposal development, performance evaluation, funder relationships
    Risk focus Regulatory and financial non-compliance Strategic misalignment, missed opportunities, weak outcomes
    Reference frameworks (illustrative) Uniform Guidance (2 CFR 200), UKRI grant terms, TRAC Institutional research strategy, funder mission fit, ARMA/EARMA/NCURA practice guidance

    In practice, smaller research offices often collapse both functions into a single “research administrator” or “grants officer” role covering the full sponsored research administration remit. Larger institutions tend to separate them, with pre-award research administration and post-award research administration teams sitting either side of the award-negotiation handover point.

    Common questions on grant administration vs grant management

    What is the difference between a grant administrator and a grant manager?

    A grant administrator is primarily responsible for post-award compliance — budget monitoring, financial reporting, and adherence to funder terms. A grant manager oversees the fuller grant lifecycle, including opportunity identification, proposal strategy, and performance outcomes, though in smaller teams one person often holds both responsibilities.

    Is administration higher than management?

    Not in the grants context specifically. Generically, “administration” can refer to policy-setting and “management” to implementation, but within sponsored programmes offices the two are parallel functions — compliance-focused versus strategy-focused — rather than a strict seniority hierarchy. Either role can sit at director level depending on institutional structure.

    What is grant administration?

    Grant administration is the post-award compliance function that ensures grant funds are spent, tracked, and reported according to the funder’s contractual terms. It covers financial oversight, effort reporting, cost-transfer approval, and the preparation of interim and final reports to the awarding body.

    What is the grants management cycle?

    The grants management cycle is the recurring sequence of opportunity identification, proposal development, award negotiation, post-award delivery, monitoring, and closeout evaluation. Lessons from closeout typically feed back into the next round of opportunity identification, making it a continuous rather than linear process.

    Why the distinction matters for research offices

    Blurring grant administration and grant management has real operational costs. Institutions that treat the two as interchangeable often end up with compliance gaps — a research office focused entirely on winning new awards can miss cost-transfer deadlines or effort-reporting certifications, triggering audit findings. Conversely, an office staffed only with compliance-minded administrators can under-invest in the proposal development and funder-relationship work that keeps the award pipeline healthy.

    Professional bodies on both sides of the Atlantic reflect this split in how they organise practice guidance and training. NCURA (US) and EARMA and ARMA (UK/Europe) both maintain competency frameworks that separate pre-award and post-award skill sets, and INORMS’ Research Management and Administration career framework explicitly distinguishes strategic research management from operational research administration. This is not a CASRAI-specific taxonomy — it reflects how the wider research administration profession itself is organised, and institutions building or restructuring a sponsored programmes office should map roles against it rather than inventing local terminology from scratch.

    The distinction also matters for how institutions define career pathways. A research administration career track built purely on compliance risks losing staff who want strategic exposure; a track built purely on management risks producing officers who cannot pass an audit. The strongest sponsored programmes offices deliberately rotate staff across both functions, or pair a compliance-trained administrator with a strategy-trained manager on the same award portfolio.

    Looking ahead: convergence, not confusion

    As grant management systems increasingly automate routine compliance checks — flagging over-budget cost centres or missing certifications automatically — the administrative workload is shifting from manual reporting toward exception handling and judgement calls. That frees grant administrators to take on more of the performance-monitoring work traditionally associated with grant management, and the two functions are likely to converge further at the operational level even as they remain distinct in scope and risk ownership.

    For research offices building or auditing their own structure, the practical takeaway is not to pick one term over the other but to be explicit about which lifecycle stage — and which risk — each role is actually responsible for. That clarity, more than the job title itself, is what keeps sponsored research compliant, competitive, and well governed.

  • Grants Functional Standard: What UK Funders and Institutions Need to Know

    What Is the Grants Functional Standard (GovS 015)?

    The Grants Functional Standard — Government Functional Standard GovS 015: Grants — is the Cabinet Office document that sets mandatory expectations for how UK central government departments and their arm’s-length bodies (ALBs) design, award, monitor and close out grants. First published in December 2016 and periodically updated since, it applies to any organisation administering grants wholly or partly using Exchequer funding, which in practice includes many universities, research charities, learned societies and sector bodies that receive or pass through public grant money.

    The standard operates on a “comply or explain” basis: bodies within scope must either meet the ten Minimum Requirements or record a documented justification for departing from them. It sits alongside the wider suite of UK government functional standards (covering areas such as finance, commercial and project delivery), which exist to give civil servants and delivery partners a consistent, shared language for governance and assurance.

    The Ten Minimum Requirements

    GovS 015 is operationalised through ten numbered Minimum Requirements, each with its own supporting guidance document published by the Government Grants Management Function (GGMF). Together they cover the full grant lifecycle, from senior accountability through to reconciliation and training.

    Minimum Requirement Focus area
    1. Senior Officer Responsible for a Grant Named senior accountability for each grant scheme
    2. Governance, Approvals & Data Capture Sign-off routes and central grant-data recording
    3. Complex Grants Advice Panel (CGAP) Mandatory referral for high-risk or priority schemes
    4. Business Case Development Rationale, options appraisal and value for money
    5. Competition for Funding Fair, open, proportionate award processes
    6. Grant Agreements Terms, conditions and use of the Model Grant Agreement
    7. Risk, Controls and Assurance Fraud risk, security risk and internal controls
    8. Performance and Monitoring In-year tracking of delivery against milestones
    9. Annual Review and Reconciliation Year-end financial and delivery reconciliation
    10. Training Competency requirements for grant-making staff

    Minimum Requirement 7 — Risk, Controls and Assurance — is the section research administrators should watch most closely, because it is the one most recently amended.

    What Changed in the 21 May 2026 Update

    On 21 May 2026, the Cabinet Office published a revised version of Minimum Requirement 7: Risk, Controls and Assurance. Two substantive changes were made:

    • The language governing Fraud Risk Assessments was strengthened, tightening the expectation that grant-making bodies produce and evidence a documented fraud risk assessment as part of the standard’s risk-management requirements.
    • A new paragraph (paragraph 23) was added to provide further guidance on security risk, extending the section’s scope beyond financial and delivery risk to explicitly cover security considerations in grant-funded activity.

    This update did not change the ten-requirement structure of GovS 015 itself; it refined the assurance expectations sitting underneath Minimum Requirement 7. It follows a pattern of incremental, dated revisions the GGMF has made to individual Minimum Requirement documents over recent years — CGAP referral criteria and the Grant Agreements guidance have both been revised on a similar rolling basis. For any body already running a Grants Continuous Improvement Assessment against the standard, the May 2026 wording is the version that self-assessment evidence should now reference.

    Grant Administration, Grant Management and the Centre of Excellence

    GovS 015 sits inside a broader UK government grants ecosystem, and the terminology is often used loosely. It is worth distinguishing the parts precisely, since institutions applying the standard need to know which body owns which function.

    • Grant administration refers to the operational, transactional tasks of running a grant scheme — issuing agreements, processing claims, recording data and reconciling payments.
    • Grant management is the broader discipline: strategic design of a scheme, risk appraisal, performance oversight and continuous improvement, of which administration is one component.
    • The Government Grants Management Function (GGMF) is the cross-government function, hosted by the Cabinet Office, responsible for GovS 015 itself and for coordinating grant-making practice across departments and ALBs.
    • The Grants Centre of Excellence is the operational and advisory capability that supports departments in applying the standard consistently — providing guidance, training and shared services rather than setting the standard itself.

    What is the functional standard for grants?

    It is Government Functional Standard GovS 015, the Cabinet Office document setting mandatory requirements for how UK departments and arm’s-length bodies administer grants funded wholly or partly through the Exchequer. It exists to ensure consistency, regularity and propriety in grant-making and to promote value for money in publicly funded grant schemes.

    What are UK government functional standards?

    Functional standards are Cabinet Office-issued documents that set mandatory (“shall”) and advisory (“should”) expectations for specific government functions — finance, commercial, project delivery and grants among them. They use a shared glossary so departments and their delivery partners work to a common, auditable set of definitions and controls.

    What is the difference between grant administration and grant management?

    Grant administration is the transactional layer — agreements, claims, payments and record-keeping. Grant management is the wider strategic discipline covering scheme design, risk assessment, performance monitoring and continuous improvement, within which administration operates as one supporting activity, not a synonym for the whole function.

    What is the Grants Centre of Excellence?

    It is the cross-government advisory and capability-building resource that helps departments and arm’s-length bodies apply GovS 015 in practice, through guidance, training and shared tools. It supports implementation of the standard; it does not itself author or amend the Minimum Requirements, which remain the responsibility of the Government Grants Management Function.

    Implications for Research-Funded Institutions

    Universities, research charities and sector bodies that receive Exchequer-funded grants — directly from departments or via an ALB — sit within scope of GovS 015 even when they are not themselves a government department. The May 2026 changes to Minimum Requirement 7 have practical consequences for research administration teams:

    • Grant applications and renewals may face closer scrutiny of documented fraud risk assessments, particularly for schemes flagged as complex or high-value.
    • Institutions handling sensitive research areas — dual-use technology, critical infrastructure, or international collaboration — should expect funders to reference the new security-risk paragraph when setting due-diligence conditions.
    • Research offices that already map their processes against Minimum Requirements 1–10 for continuous-improvement self-assessment should update their MR7 evidence base to the 21 May 2026 wording.
    • Grant agreement templates and internal risk registers referencing MR7 should be checked against the current guidance rather than an earlier cached version, since the GGMF revises individual Minimum Requirement documents on a rolling basis rather than reissuing the whole standard.

    None of this changes the fundamentals of good research administration practice — due diligence, documented risk assessment and clear accountability were already core expectations. What changes is the explicitness with which fraud and security risk must now be evidenced under MR7.

    Looking Ahead

    GovS 015 has been revised incrementally rather than replaced outright since 2016, and the pattern is likely to continue: individual Minimum Requirement documents updated as risks evolve, rather than a full standard rewrite. Institutions that treat the standard as a living compliance baseline — checking dated guidance documents against their internal risk frameworks at each award cycle — will be better placed than those that rely on a static PDF saved years ago. For research administrators, the practical takeaway from the 21 May 2026 update is straightforward: fraud risk assessment and security-risk screening are no longer implicit good practice under GovS 015 — they are explicit, documented expectations under Minimum Requirement 7.

  • Research Funding Cuts in the UK: How Exposed Are Institutions to US Policy Shifts?

    British universities have spent 2026 absorbing two funding shocks at once. At home, UK Research and Innovation (UKRI) is mid-way through the biggest restructuring of its funding model since the body was created in 2017. Abroad, the US administration’s proposed reductions to federal science budgets have destabilised grant pipelines that many UK research groups quietly depend on. Research funding cuts in the UK are no longer a purely domestic story — they are increasingly a function of decisions taken in Washington, and institutions that have not mapped their transatlantic exposure are flying blind into 2027 planning cycles.

    The transatlantic funding shock: what changed in 2026

    On the UK side, the Department for Science, Innovation and Technology and UKRI confirmed in late 2025 how £38.6 billion of public R&D funding would be distributed over the following four years. The overall UKRI budget is set to rise towards £10 billion a year by 2030, but the distribution model has shifted to three “funding buckets”: curiosity-driven research, strategic government and societal priorities, and support for innovative companies — each intended to represent roughly half, a quarter and a quarter of spend respectively.

    That restructuring has not been smooth. In early 2026, three research councils — the Medical Research Council, the Biotechnology and Biological Sciences Research Council, and the Engineering and Physical Sciences Research Council — paused active grant routes. The Science and Technology Facilities Council separately confirmed it must find £162 million in cost reductions by 2029–30, driven by rising energy costs and unfavourable currency exchange rates, forcing project leaders to model cuts of 20%, 40% and even 60% to national facilities, particle physics and astronomy programmes. The House of Commons Science, Innovation and Technology Committee has since pressed UKRI’s chief executive for clearer, comparable data on the allocation changes.

    On the US side, the picture is starker still. The Association of American Universities has tracked administration proposals to cut federal research funding by 22% overall and basic research by 34% in a single fiscal year, with the Brennan Center for Justice estimating Congress was asked to strip an additional $44 billion from scientific research. The Center for American Progress estimates that National Institutes of Health (NIH) and National Science Foundation (NSF) cuts alone could cost the US economy $10–16 billion annually. Grant holds affecting Harvard and other institutions persisted well into 2026, with the NSF only lifting some holds in late May after sustained press scrutiny.

    How exposed are UK institutions to US funding shifts?

    The US is the UK’s single largest research collaborator by volume of co-authored output, and that collaboration runs through several distinct funding channels — each with a different risk profile. Institutions that treat “US exposure” as a single number miss where the real fragility sits.

    Exposure channel What is at risk 2026 signal UK mitigation lever
    Direct US federal co-funding Joint grants and sub-awards linked to NIH/NSF cycles NSF grant holds affecting Harvard and peer institutions persisted into May 2026 UKRI’s bucket reform reduces reliance on any single funding stream
    US philanthropic and foundation funding Foundation grants sensitive to the wider US fiscal and political climate US philanthropic sector under pressure to backfill federal shortfalls UK trusts, Horizon Europe association, and international co-funding
    Industry and corporate R&D partnerships Private R&D spend that tracks federal grant cycles US firms reassessing R&D allocation amid budget uncertainty UK government talent and relocation schemes attracting redirected private investment
    Talent pipeline Researchers on US-funded fellowships or joint appointments Early-career researchers facing contract non-renewal in the US UK schemes offering relocation funding for research teams

    Institutions with heavy involvement in biomedical, physics or environmental science co-funding arrangements are typically the most exposed, since these fields have historically carried the largest NIH and NSF footprints in joint UK-US work. Smaller specialist units embedded in a single US-funded programme carry proportionally more risk than large, diversified research portfolios — a distinction that should inform any institutional risk register.

    Answer-first: what researchers and administrators are asking

    Did research funding get cut?

    Yes, on both sides of the Atlantic. The UK’s Science and Technology Facilities Council confirmed £162 million in cost reductions by 2029–30, and three UKRI councils paused grant routes in early 2026. In the US, the administration proposed cutting overall federal research funding by 22% and basic research by 34% in a single fiscal year.

    Are universities getting less funding?

    Universities UK estimates that government policy decisions will reduce funding to English higher education providers by roughly £3.7 billion between 2024–25 and 2029–30. Combined with flat UKRI settlements and paused grant schemes, most English research-intensive institutions face a genuinely tighter funding environment than in the previous spending review period.

    Which UK universities are in financial trouble in 2026?

    The Office for Students has repeatedly flagged a growing minority of English providers running operating deficits, driven by falling international student income, domestic fee stagnation, and rising costs. This is a distinct pressure from research-specific council cuts, but the two compound: institutions under financial strain have less capacity to cushion research funding shocks internally.

    Why did Harvard get funding cut?

    Harvard University was among several US institutions to have NIH and NSF grants held or paused amid federal disputes over campus policy compliance. The NSF lifted some of these holds in May 2026 following media inquiries, but the episode illustrates how US federal research funding can be withdrawn on non-scientific grounds — a governance risk UK partners inherit indirectly through joint grants.

    UKRI’s own reforms as a partial buffer

    UKRI’s shift to a three-bucket funding model is contested — the Campaign for Science and Engineering has pushed UKRI for clearer year-on-year comparability, and the reform has coincided with disruptive grant pauses. But structurally, it offers UK institutions something the pre-2025 model did not: an explicit, published split between curiosity-driven research, strategic priorities, and innovation support, rather than allocation by historical research-council silos alone.

    • A published macro-level split (roughly 50% curiosity-led, 25% strategic priorities, 25% innovative companies) gives institutions a clearer basis for forecasting than opaque, council-by-council settlements.
    • UKRI has committed to providing high-level historical mapping so institutions can benchmark the new buckets against prior allocations.
    • The overall UKRI budget trajectory — rising toward £10 billion a year by 2030 — provides a growing (if unevenly distributed) domestic base that partially offsets US-side volatility, provided institutions position themselves across more than one bucket.

    None of this eliminates the pain of near-term grant pauses. But a funding architecture built around explicit strategic categories is inherently easier to diversify across than one built purely on discipline-specific council budgets — which is precisely the structural weakness that has made STFC-funded physics and astronomy groups disproportionately exposed to the current cuts.

    The case for diversification

    The practical lesson for institutional leaders is not to retreat from US collaboration — the scientific and reputational value of transatlantic partnerships remains real — but to stop treating single-source dependency as a manageable risk. UK government initiatives, including relocation-funded schemes aimed at researchers whose US positions have become uncertain, are a useful signal of where institutional and national strategy are converging, but they do not substitute for individual institutions actively rebalancing their own portfolios.

    • Map grant portfolios by funding channel (federal co-funding, philanthropic, industry, talent) rather than by discipline alone, so exposure is visible at the funding-source level, not just the subject level.
    • Treat Horizon Europe association and other multilateral schemes as genuine substitutes for at-risk US federal streams, not merely as supplementary income.
    • Build philanthropic and industry diversification into research strategy documents explicitly — the approach several research-intensive universities, including Cambridge, have already formalised.
    • Use grants management functions to track funder-level concentration risk as a standing item in institutional risk registers, not an ad hoc exercise triggered only after a funding shock.

    What this means for research administrators

    For research administration teams, the near-term task is unglamorous but essential: build an accurate, funder-level map of institutional exposure before the next funding cycle, not after it. That means treating grants management as a strategic function that sits alongside — not beneath — research strategy, with clear visibility into which grants, fellowships and facility partnerships sit on which side of the Atlantic.

    Longer term, the institutions that weather 2026’s funding turbulence best will likely be those that used UKRI’s bucket reform as an opportunity to rebalance rather than a bureaucratic inconvenience to endure. Diversification is not a hedge against any single government’s budget decisions — it is increasingly the baseline condition for research resilience.

    CASRAI’s work on the research administration function, including standards for describing contributor roles and institutional research infrastructure, sits alongside this diversification agenda — see the research administration resources, and browse funding and grants terminology in the CASRAI Dictionary.

  • University Research Funding Cuts: What the Court Cases Mean for Grant Recipients

    University research funding cuts have moved from budget-line disputes into federal courtrooms. Since April 2025, Harvard, Columbia and coalitions of state attorneys general have filed parallel legal challenges against the National Institutes of Health (NIH) and National Science Foundation (NSF) over grant terminations, funding freezes and new indirect-cost caps. The cases differ in posture — one produced a court ruling, one produced a settlement, others remain active — but together they are setting the procedural rules that will govern how frozen, denied or withdrawn grants get reviewed for years to come.

    For research offices, the practical question is no longer whether litigation is happening but what it is actually requiring agencies and institutions to do while cases proceed. This analysis sets out the pattern, compares the major tracks, and lists what sponsored-programs and general counsel offices should be monitoring now.

    The pattern: why universities are suing over federal funding

    Beginning in early 2025, the administration froze, terminated or delayed thousands of federal research awards to universities, citing diversity, equity and inclusion (DEI) content, alleged civil-rights failures, or new indirect-cost policy. According to a mapping analysis by the Center for American Progress, more than 4,000 grants across over 600 institutions were targeted for termination, with claimed award values between roughly $6.9 billion and $8.2 billion.

    Universities and state attorneys general responded with a consistent legal theory: that agencies violated the Administrative Procedure Act (APA) by acting in an “arbitrary and capricious” manner, skipping required notice-and-comment procedures, or exceeding authority Congress had granted them. In several cases, plaintiffs also raised First Amendment retaliation claims, arguing that funding was cut in response to institutional speech or governance decisions rather than for programmatic reasons.

    • Institutional suits — Harvard sued the federal government directly over a frozen $2.2 billion in grants and contracts.
    • Negotiated settlements — Columbia resolved its dispute through a financial and compliance agreement rather than litigating to judgment.
    • Multi-state actions — coalitions of state attorneys general sued NIH and NSF separately, challenging both DEI-related terminations and the NSF’s 15% indirect-cost cap.

    Harvard, Columbia and the multi-state track record

    The three tracks have produced different outcomes, which matters for institutions trying to predict what a given legal strategy is likely to achieve.

    Track Funding at stake Legal basis Outcome so far
    Harvard v. federal government ~$2.2 billion frozen (April 2025) APA “arbitrary and capricious”; First Amendment retaliation District court ruled the cuts unlawful (September 2025); the Department of Justice subsequently sued Harvard (March 2026) seeking to recoup funds and contest the ruling
    Columbia University ~$400 million cut (March 2025) Civil-rights compliance dispute; no APA suit litigated to judgment Settled for $221 million (July 2025) — $200 million civil-rights, $21 million employment claims; ~$400 million in research funding reinstated; increased federal oversight and reporting requirements
    Multi-state AGs v. NIH Hundreds of grants (DEI, transgender health, vaccine-hesitancy research) APA violations; exceeded statutory authority Settlement committed NIH to its “usual process” for grant review; a court separately ruled roughly 900 terminated grants unlawful and ordered reinstatement, though the administration has appealed
    Multi-state AGs (16 states) v. NSF STEM diversity programmes; 15% indirect-cost cap APA and constitutional claims regarding congressional intent Litigation ongoing; plaintiffs are seeking to block the indirect-cost cap and reverse related terminations

    Harvard’s case is the clearest judicial precedent to date: a U.S. District Court in Boston found the government’s cancellation unlawful and ordered funding restored, only for the Department of Justice to open a separate recoupment suit months later — a reminder that a favourable ruling does not end the underlying dispute. Columbia’s settlement, by contrast, traded a fixed financial payment and expanded oversight for the reinstatement of frozen funds without a court ruling on the merits.

    What the settlements and court orders have required so far

    Three concrete procedural requirements have emerged from this litigation, and they matter more to research administrators than the headline dollar figures:

    • NIH’s court-ordered grant review. Following the ruling that roughly 900 terminated grants were unlawfully cancelled, NIH was ordered to reinstate them and, in a related settlement, committed to returning to its “usual process” for reviewing applications rather than applying ad hoc political criteria.
    • Reinstatement is not automatic. Reporting has repeatedly noted that court-ordered reinstatements are not occurring uniformly across all affected grants or states, and that the administration has filed appeals that keep some awards in limbo even after a favourable ruling.
    • Settlements bundle funding with oversight. Columbia’s agreement did not simply restore money; it added federal reporting obligations on admissions and international-student data and required adoption of the IHRA definition of antisemitism — a template that later negotiations may echo.

    None of this activity has produced a single, uniform national standard. Each institution’s relief depends on its specific docket, its circuit, and whether it litigated to judgment or settled.

    Frequently asked questions

    Why did Harvard get its research funding cut?

    The administration froze roughly $2.2 billion in Harvard grants and contracts in April 2025, citing the university’s response to campus antisemitism concerns and its refusal to comply with a set of governance demands. Harvard sued, arguing the freeze violated the Administrative Procedure Act and the First Amendment.

    Why is Columbia University losing funding?

    Columbia had roughly $400 million in federal grants terminated in March 2025 over alleged civil-rights compliance failures related to campus antisemitism. Rather than litigate, Columbia negotiated a $221 million settlement in July 2025 that restored most of the frozen research funding in exchange for expanded federal oversight.

    Was terminated NIH research funding actually reinstated?

    Partially. A court ordered roughly 900 NIH grants reinstated after finding their termination unlawful, but subsequent reporting found reinstatement was inconsistent across institutions and states, and the administration has appealed the underlying ruling, leaving some awards unresolved.

    What should a research office track during active litigation?

    Research offices should track award status changes, agency guidance updates, court docket entries affecting their sponsors, and internal expenditure and indirect-cost documentation — the same records needed both for compliance and for supporting institutional legal counsel if a grant is challenged.

    What research offices should track while litigation is pending

    Regardless of whether an institution is a named party, sponsored-programs and research-administration offices with active NIH or NSF awards should maintain contemporaneous records across five areas:

    • Correspondence with program officers — emails, termination or stop-work notices, and summaries of calls, since these documents establish the factual record if an award is later challenged.
    • Award terms and modifications — particularly termination, suspension and indirect-cost clauses, which vary by grant vintage and mechanism.
    • Expenditure and indirect-cost documentation — detailed enough to substantiate negotiated facilities-and-administrative rates if a cap or clawback is contested.
    • Docket activity relevant to the sponsoring agency — court orders, appeals and settlement terms that could reinstate, further freeze, or attach new conditions to an award.
    • Contingency and bridge-funding plans — since even a favourable ruling can take months to translate into disbursed funds, as Harvard and NIH grantees have both experienced.

    Institutions should also coordinate closely with general counsel before responding to any new agency demand tied to a settlement template, since Columbia’s agreement shows that funding restoration can come bundled with reporting and governance conditions extending well beyond the original grants at issue.

    Implications and what comes next

    The litigation pattern suggests two durable lessons for institutional research offices. First, a court ruling in an institution’s favour does not guarantee funds will flow on the original schedule — reinstatement has proven uneven, and follow-on actions such as the Department of Justice’s suit against Harvard show that disputes can continue well after an initial win. Second, settlement and litigation are not mutually exclusive strategies within a single funding relationship: an institution can win a ruling on one set of terminated NIH awards while separately negotiating conditions with another agency, or facing new litigation over the same funds.

    For offices managing sponsored research and research administration more broadly, the operational takeaway is procedural discipline rather than prediction. Consult the CASRAI Dictionary for definitions of the compliance and funding terms surfacing in this litigation, and treat every termination notice, court order and settlement condition as part of a single evidentiary record — because in this funding environment, that record is what any given grant’s outcome will ultimately turn on.

  • mRNA Research Funding Cuts: Tracking the Institutional Fallout

    The 2026 research-funding landscape has a new, narrower fault line: mRNA research funding cuts tied specifically to the messenger-RNA vaccine platform, distinct from the broader reductions affecting cancer and biomedical research generally. On 5 August 2025, the US Department of Health and Human Services (HHS), under Secretary Robert F. Kennedy Jr., announced it was winding down mRNA vaccine development activities administered through the Biomedical Advanced Research and Development Authority (BARDA), terminating or restructuring 22 contracts worth nearly $500 million. Nearly a year on, the institutional fallout is now measurable, and research offices are adjusting their portfolios in response.

    What changed: HHS and BARDA’s mRNA wind-down

    The August 2025 announcement marked a deliberate shift in federal biomedical strategy: HHS stated it would move BARDA’s pandemic-preparedness investment away from mRNA platforms for respiratory viruses and toward what officials described as “safer, broader vaccine platforms.” The decision followed an earlier, separate cancellation of a roughly $600 million Moderna contract for a pandemic influenza mRNA vaccine in May 2025 — a move HHS and Moderna both describe as distinct from the August action, though the two together set the tone for the year’s mRNA-specific retrenchment.

    The August wind-down did not apply uniformly. According to contract-level reporting from HHS and trade press, the 22 affected awards fell into four categories:

    • Terminated contracts — awards cancelled outright, ending federal support for the specific project.
    • De-scoped work — existing contracts kept alive but with mRNA-specific tasks removed or reduced.
    • Rejected or withdrawn solicitations — proposals for new mRNA work that were declined before an award was made.
    • Restructured collaborations — joint projects renegotiated to change or remove the RNA component.

    Nature’s editorial board called the cancellations “the highest irresponsibility,” noting that a related executive order gives political appointees expanded authority over federal research-grant decisions — a governance change research offices should track independently of the funding total itself, since it affects how future awards in adjacent fields may be reviewed.

    Which institutions and companies have reported losses

    Public reporting to date identifies a specific set of universities, biotechs and pharmaceutical partners affected by the BARDA wind-down, each experiencing a different type of impact:

    Organisation Type of impact Project area
    Emory University Contract terminated Inhaled dry-powder mRNA antiviral platform
    Tiba Biotech Contract terminated RNA interference (RNAi) therapeutic — company disputes classification as an mRNA vaccine project
    Luminary Labs, ModeX, Seqirus Scope reduced mRNA-related tasks removed from existing BARDA agreements
    Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone Proposal rejected New mRNA-related solicitations declined pre-award
    AAHI, AstraZeneca, HDT Bio, Moderna/UTMB Collaboration restructured Nucleic-acid vaccine partnerships renegotiated

    Emory’s public statement was measured — a spokesperson said the university would “adjust as needed to pursue our research goals and ambitions” — but a lead researcher on the inhaled-platform project told local press the cuts risk signalling that mRNA is no longer a viable federal research priority, a concern echoed across the affected cohort.

    The scale of what is at stake extends well beyond the 22 terminated awards. A cross-sectional study published in JAMA Network Open, led by a team including researchers at Northwestern University and the University of Virginia, catalogued 178 active NIH grants related to RNA vaccines awarded between 1997 and 2025, representing $1.65 billion in cumulative federal investment. Those grants produced 2,342 publications and nearly 150,000 citations; 35% were cited in clinical trials or practice guidelines, and 18 were awarded through the Small Business Innovation Research and Small Business Technology Transfer programmes — the mechanism many university spinouts rely on to commercialise federally funded research. An accompanying commentary from researchers at the University of Calgary and University of Saskatchewan warned that excising RNA vaccine research from the NIH portfolio “is antithetical to current goals of making America healthy,” and separately noted that current-season flu vaccines are poorly matched to circulating strains — an argument for, not against, continued RNA platform investment.

    A Yale School of Public Health report has separately warned of downstream health consequences from the funding cancellation, and the American Lung Association and Harvard T.H. Chan School of Public Health have both published concern statements specifically about the loss of mRNA vaccine development capacity for respiratory disease.

    Common questions on the mRNA funding rollback

    Is the Moderna contract cancelled?

    Two separate Moderna contracts were affected. HHS cancelled a roughly $600 million bird-flu mRNA vaccine contract in May 2025, and Moderna’s collaboration with the University of Texas Medical Branch was restructured — not fully terminated — as part of the August 2025 BARDA wind-down.

    Why did the FDA reject Moderna’s mRNA flu vaccine application?

    The FDA said it refused to review Moderna’s mRNA flu vaccine filing because the company had not tested the product against a CDC-recommended comparator vaccine in a head-to-head clinical trial, as agency guidance issued in 2024 required — a regulatory, not funding, decision that compounds the platform’s commercial headwinds.

    How research offices are hedging portfolio risk

    Institutional research offices with active or pending mRNA-related awards are responding in broadly consistent ways, even where individual contract outcomes differ:

    • Diversifying platform exposure — reframing single-platform mRNA proposals as multi-modal nucleic-acid or protein-subunit programmes to reduce reliance on one federal funding line.
    • Pursuing non-federal co-funding — several affected groups, including Tiba Biotech, have publicly stated intent to pursue philanthropic, state-level, or industry funding to continue work federal contracts previously covered.
    • Auditing award language for termination clauses — sponsored-programmes offices are reviewing existing BARDA and NIH awards for early-termination-for-convenience language, which was the operative mechanism in several August 2025 cancellations.
    • Separating cancer-mRNA and infectious-disease-mRNA portfolios — because the HHS wind-down targeted respiratory-virus vaccine platforms specifically, institutions with mRNA cancer-vaccine work are treating that portfolio as distinct in risk profile, even though it uses overlapping delivery technology.

    For research administration offices, this is a live case study in sponsor-concentration risk — the same principle that underpins diversified grant portfolios more broadly. Institutions tracking these developments alongside broader shifts in research administration practice are better positioned to model exposure across single-sponsor dependencies before the next policy shift, rather than after.

    Outlook: what research administrators should track next

    The mRNA-specific rollback is narrower than the broader federal research-funding contraction affecting NIH and cancer research overall, but its concentration in a single platform and a single agency relationship (HHS/BARDA) makes it a useful, contained case study in how quickly a funding line can be repriced on policy grounds rather than scientific merit. Three signals are worth monitoring going into the next budget cycle: whether the executive order expanding political appointee authority over grant decisions is applied beyond mRNA to other platforms; whether the $1.65 billion NIH RNA-vaccine grant base identified in the JAMA Network Open study sees further reductions at renewal; and whether affected institutions successfully replace lost BARDA funding with non-federal sources, which would signal a durable shift in how pandemic-preparedness research is financed. Research offices with mRNA-adjacent portfolios should treat this episode as a template for stress-testing single-sponsor concentration risk across all federally funded platforms, not just this one.

  • Cancer Research Funding Cuts: What the 2026 NIH Data Shows

    Search interest in cancer research funding cuts has spiked through the first half of 2026, tracking a wave of NIH award terminations, a proposed 37% cut to the National Cancer Institute’s budget, and a roughly $500 million rollback of federal mRNA vaccine research contracts. For research administrators, the practical question is no longer whether the funding landscape has shifted — it clearly has — but how exposed a given portfolio is, and what a grants office can do about it before the next termination notice arrives.

    What the 2026 NIH Funding-Cut Data Shows

    HHS reporting released in April 2026 puts the cumulative tally of terminated National Institutes of Health awards at 1,392, with $539 million in unliquidated obligations still outstanding — funds that were committed but not yet disbursed when the terminations took effect. That figure sits alongside an earlier, broader accounting: a PubMed Central analysis found that by June 2025, roughly 2,300 NIH grants worth nearly $3.8 billion had already been cancelled agency-wide, including more than 160 cancer-related clinical trials.

    The cuts are not evenly distributed across the calendar. A May 2025 US Senate HELP Committee Minority Staff report found the administration cut approximately $2.7 billion in NIH funding during the first three months of 2025 alone, with cancer-specific research funding down 31% for that quarter compared with the same period in 2024. On the budget side, the National Cancer Institute’s own FY2026 congressional justification requested $4.53 billion — a $2.69 billion, or 37.3%, reduction from its FY2025 level of $7.22 billion.

    • Indirect cost cap: facilities-and-administrative (F&A) reimbursement rates on NIH grants have been capped at 15%, cutting into the overhead that funds shared cores, compliance staff, and research infrastructure at host institutions.
    • mRNA-specific rollback: HHS cancelled roughly $500 million in mRNA vaccine and therapeutics research contracts during 2025, with direct knock-on effects for mRNA-based cancer immunotherapy pipelines.
    • Review bottlenecks: reporting in early 2026 described new layers of administrative review delaying disbursement of already-approved grants, with some applications flagged for specific terminology before release.

    Which Disease Areas and Grant Types Are Most Exposed

    Exposure is not uniform across tumour types. A 2025 analysis of NIH and Congressionally Directed Medical Research Programs (CDMRP) funding from 2013 to 2022, presented at the Journal of Clinical Oncology, found that funding levels correlate strongly with disease incidence (Pearson coefficient 0.85) but only weakly with mortality (Pearson coefficient 0.36) — meaning historically under-funded, high-mortality cancers have the least financial cushion to absorb further cuts.

    Cancer type Combined NIH + CDMRP funding, 2013–2022 Relative funding position
    Breast $8.36 billion Highest-funded
    Lung $3.83 billion Well-funded
    Prostate $3.61 billion Well-funded
    Hepatobiliary $1.13 billion Under-funded vs. mortality burden
    Cervical $1.12 billion Under-funded vs. mortality burden
    Uterine $435 million Lowest-funded

    Grant type matters as much as disease area. Early-stage-investigator R01s, K-series career development awards, and T32 institutional training grants have been disproportionately represented among terminations, largely because diversity, equity, and inclusion-linked language in aims or personnel sections triggered policy-based review flags. Multi-year, non-competing renewals and diversity supplement awards have also recurred repeatedly in termination letters reviewed by health-policy reporters. Large P30 cancer-centre support grants are separately exposed through the F&A cap, since their budgets rely heavily on indirect-cost recovery to fund shared facilities.

    Answer-First Q&A: Cancer Research Funding Cuts

    Why is NIH cutting cancer research funding?

    The terminations stem from a mix of executive-branch policy priorities — including the rollback of diversity, equity, and inclusion-linked research — and proposed budget reductions for FY2026 and FY2027. Congress has historically restored some NIH funding after similar proposals, but administrative terminations of already-awarded grants have proceeded independently of the appropriations process.

    How much cancer research funding has been cut?

    By April 2026, HHS reporting recorded 1,392 terminated NIH awards with $539 million in unliquidated obligations. Separately, cancer-specific funding fell 31% in the first quarter of 2025 versus the prior year, and the National Cancer Institute’s FY2026 budget request represents a 37.3% reduction from its FY2025 level.

    Which cancer types are most affected by funding cuts?

    Historically under-funded cancers with high mortality — including uterine, cervical, and hepatobiliary cancers — have the least buffer to absorb cuts, since funding has tracked incidence rather than mortality. Early-career researchers and training-grant recipients across all disease areas are also disproportionately exposed.

    What Grants Offices Can Do Now

    None of this is speculative risk anymore — it is portfolio management. Institutions with active NIH-funded cancer research should treat funding volatility as a standing operational condition rather than a one-off shock, and research administration offices should build response capacity accordingly.

    • Bridge funding: establish or expand an internal bridge-fund mechanism, paired with external bridge grants from bodies such as the American Association for Cancer Research and the American Cancer Society, to keep terminated projects and personnel intact for six to twelve months while alternative funding is secured.
    • Appeals and documentation: maintain a standing file of scientific-merit documentation for every active award so a formal reconsideration request — or, where warranted, legal challenge — can be filed quickly; several 2025 terminations were reversed after litigation established that cancellations lacked adequate scientific justification.
    • Diversified funder mix: reduce single-funder concentration risk by cultivating relationships with disease-specific foundations (for example, the V Foundation and Damon Runyon Cancer Research Foundation), state-level programmes such as Texas’s CPRIT, and international co-funding arrangements, rather than relying on NIH as the sole primary sponsor for a given research line.
    • F&A exposure modelling: run budget scenarios against the 15% indirect-cost cap now, before it applies at renewal, so cancer-centre and core-facility budgets are not caught unprepared.
    • Track funding-notice guidance: assign a named staff member to monitor NIH Notice of Funding Opportunity and Guide Notices for terminology or eligibility changes that could flag active or pending applications for review.

    Professional associations — including ARMA, NCURA, and INORMS — have begun circulating shared templates and peer intelligence on termination response, and grants offices that pool this knowledge across institutions are responding faster than those working in isolation. As the FY2027 budget cycle approaches, with a further proposed reduction to overall NIH funding under discussion in Congress, the institutions best placed to protect their cancer research portfolios will be those that treated 2025’s cuts as a stress test rather than a one-time event — and built the bridge-funding, appeals, and diversification infrastructure needed to withstand the next round.

  • Peer Review of Grant Proposals Under Political Pressure: The Case for Independence

    A funding notice should be a statement of scientific priority, not a political signal. Yet across 2025 and into 2026, the machinery that has historically separated the two — peer review grant proposals through panels of independent subject-matter experts — has come under direct pressure from proposals that would let political appointees override merit-based funding recommendations. This is an argument, not a survey: politicised screening of grant notices does not just change who gets funded, it erodes the evidentiary basis on which the public is asked to trust science at all.

    Why Independent Peer Review Underpins Public Trust

    Grant peer review exists to answer one narrow question: is this proposal, on scientific merit, worth public money? Reviewers assess feasibility, methodological rigour, and the track record of the team, insulated as far as possible from who is asking or why. UK Research and Innovation’s guidance for its research councils is explicit about this insulation: proposals go to at least three independent reviewers, comments are handled in confidence, and funders are told not to substitute journal-based metrics or reputation for direct scientific judgement, in line with the San Francisco Declaration on Research Assessment (DORA).

    That model works because it is boring by design. Merit review is meant to be the least newsworthy part of the research funding cycle — a quiet, expert, reproducible filter. When it becomes contested political territory, the filter itself becomes a variable, and every downstream claim about “the best science being funded” loses its footing.

    The 2026 Pressure Points: Political Override and Funding Cuts

    Two developments in the United States illustrate the risk. First, a proposed rule from the White House Office of Management and Budget would give political appointees at federal agencies final authority over grant funding decisions, including the ability to terminate active awards that no longer align with stated “agency priorities” or the “national interest” — language broad enough to reach almost any politically contested field, from climate science to public health. Second, budget proposals affecting the National Institutes of Health and National Science Foundation, alongside a reported NIH plan to consolidate its institutes and centres and restructure study-section peer review, have combined to shrink the pool of fundable awards even as application volume holds steady or rises.

    Neither development is hypothetical process detail. Together they change what a grant notice signals: not “this call is open to the best proposal” but “this call is open to the best proposal that also survives a discretionary political filter after review.” The Association of American Universities and multiple scientific societies have flagged this combination as a structural threat to the research enterprise, not a routine administrative reform.

    The comparison with the UK’s model is instructive, not because either system is beyond criticism, but because it shows what an evidentiary firewall between political priority-setting and technical merit assessment actually looks like in practice:

    Safeguard UKRI research council practice US 2026 OMB proposal risk
    Reviewer independence Minimum three reviewers, including one nominated by the applicant Political appointees can override expert panel recommendations
    Confidentiality Proposals handled “in confidence”; reviewer identities protected until decision No published equivalent confidentiality standard cited in the proposal
    Assessment criteria DORA-aligned; journal metrics and reputation explicitly excluded Alignment with “agency priorities” or “national interest” is an added, non-scientific criterion
    Award stability Funded projects proceed on scientific timelines set at award Active awards may be terminated mid-project if priorities shift

    Common Questions on Grant Peer Review

    What are peer-reviewed grants?

    Peer-reviewed grants are awards where an independent panel of subject-matter experts assesses a proposal’s scientific merit, feasibility, and rigour before funds are released. Agencies including NIH, UKRI, and most major foundations use this process to allocate limited public or philanthropic funding to the strongest available science, rather than by administrative discretion alone.

    What is the golden rule of peer review?

    The golden rule of peer review is to judge the work on its merits, free of conflicts of interest or external pressure. Reviewers assess methodology, evidence, and feasibility rather than the identity, politics, or institutional profile of the applicant — the same principle that underlies publication peer review under bodies such as COPE and ICMJE.

    What are the key elements of grant peer review?

    Core elements include reviewer expertise, documented conflict-of-interest management, confidentiality of unpublished ideas, structured and consistent scoring criteria, and a documented decision trail. Removing any one element — for example, by inserting a discretionary political override after panel scoring — weakens the evidentiary chain the whole process is meant to produce.

    What Politicised Review Does to the Evidence Base

    Research administrators should treat this as an evidentiary problem before it is a funding problem. If a funding decision can be overridden on non-scientific grounds after expert review, the review itself stops functioning as reliable evidence of merit — for auditors, for future meta-research, and for the public record. That has knock-on effects:

    • Grant history becomes an unreliable signal for institutional research assessment and future funder due diligence.
    • Researchers in politically sensitive fields face a de facto chilling effect, shaping what gets proposed long before any panel convenes.
    • Cross-border collaborations and co-funding arrangements, for example with Horizon Europe partners, become harder to underwrite if one partner’s award pipeline is subject to discretionary termination.
    • Standardised, interoperable research-administration infrastructure — persistent identifiers, contributor role taxonomies, funder metadata — loses value if the funding decisions it documents are not reliably merit-based.

    Forward Look: How Institutions Can Preserve Merit Review

    Research offices and institutional leaders are not bystanders here. Several concrete, defensible steps can preserve the evidentiary integrity of merit review even where political pressure on funders intensifies:

    • Document review outcomes independently. Retain institutional records of panel scores and reviewer comments separate from final award notices, so a political override is auditable rather than silent.
    • Diversify funding portfolios. Reduce single-funder dependency so that one agency’s discretionary process does not determine an entire research programme’s viability.
    • Support reviewer capacity. Volunteer reviewing is already strained by rising application volumes; institutions that credit peer-review service in promotion and workload models help sustain the expert pool the whole system depends on.
    • Use standardised, verifiable metadata. Persistent identifiers and transparent contribution records make it harder to quietly substitute political criteria for merit criteria after the fact, and easier for auditors and journalists to reconstruct what actually happened.

    None of this substitutes for the underlying policy fight over whether political appointees should hold override authority at all. But it is what research administration can control while that fight plays out — and it rests on the same logic as standardised, verifiable contribution frameworks such as CRediT, which CASRAI originated in 2014 as an interoperable way to document who did what on a piece of research; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. Merit-based science depends on infrastructure that makes evidence, including evidence of how funding decisions were actually made, auditable rather than assumed.

  • Grant Peer Review Under OMB’s Proposed 2026 Uniform Grants Regulation

    The Office of Management and Budget (OMB) has proposed a rewrite of the federal government’s grant-making rulebook that would change how grant peer review functions across agencies including the National Institutes of Health (NIH), the National Science Foundation (NSF) and the Department of Energy. According to reporting from STAT News, Inside Higher Ed, Science and NPR, the draft rule would convert the long-standing “Uniform Guidance” (2 CFR Part 200) into a binding “Uniform Grants Regulation,” subordinating scientific merit review to a new layer of political sign-off and giving agency political appointees explicit authority to terminate awards that no longer track administration priorities.

    For research administrators, the proposal is not a routine compliance update. It touches the mechanism — independent expert review — that has underpinned federal research funding decisions for more than half a century.

    What OMB’s Proposed Grants Rule Changes

    Uniform Guidance governs financial assistance rules across virtually every federal grant-making agency, covering everything from allowable costs to audit requirements. OMB’s proposal would elevate that guidance to a binding regulation and layer several new mechanisms on top of it. The core changes reported by STAT, Inside Higher Ed, Science and NPR include:

    • A mandatory pre-issuance review of discretionary grant awards by senior political appointees before funds are released.
    • Reclassification of peer-review recommendations as advisory rather than binding or routinely deferred to.
    • An undefined “Gold Standard Science” criterion appointees may apply during sign-off.
    • Expanded termination authority for awards deemed misaligned with agency priorities, including multi-year awards already underway.
    • New pre-approval requirements for costs tied to publications, conference attendance and journal subscriptions.
    • A “domestic-first” preference framework for research and development awards.
    • Prohibitions on funding tied to diversity, equity and inclusion (DEI) activities, “gender ideology,” or research supporting disparate-impact liability theories.
    • Elimination of fixed-amount subawards.

    The public comment period is reported to close on 13 July 2026, with an anticipated effective date of 1 October 2026 if the rule is finalised largely as proposed.

    From Deference to “Advisory”: How Peer Review’s Role Shrinks

    Under current practice, agencies such as NIH route applications through scientific review groups or study sections, which score proposals on significance, approach, innovation and investigator qualifications. Program officials retain formal award authority, but in practice they defer heavily to review scores and percentile rankings to set paylines.

    The proposed rule text, as reported across multiple outlets, states that peer-review recommendations “are not ministerially ratified, routinely deferred to, or otherwise treated as de facto binding” by senior appointees. That is a structural change: a proposal that clears scientific review with a strong score could still be delayed, reprioritised or rejected at a political pre-issuance gate that sits above the merit-review process rather than alongside it.

    Research associations — including the Association of Public and Land-grant Universities (APLU), the American Association for Cancer Research (AACR) and the Computing Research Association (CRA) — have raised concerns that the change would insert non-scientific criteria into funding decisions that have historically been insulated from politics precisely to protect scientific rigour and public trust.

    Aspect Current practice Proposed rule
    Peer-review status De facto determinative for most competitive awards Explicitly advisory
    Final sign-off Program/agency officials, largely deferential to review scores Senior political appointees, mandatory pre-issuance review
    Termination grounds Non-compliance, budget, performance Adds “no longer aligned with agency priorities,” including mid-award
    Allowable costs Publications, conferences, subscriptions generally allowable Pre-approval required for these cost categories
    Subaward mechanism Fixed-amount subawards permitted Fixed-amount subawards eliminated

    Grant Peer Review: Common Questions Answered

    What is a peer-reviewed grant?

    A peer-reviewed grant is funding awarded after independent subject-matter experts assess a proposal’s scientific merit — its significance, approach, feasibility and investigator qualifications — typically through a scored study section or review panel. At NIH, review groups assign priority scores that traditionally shape funding decisions, though final award authority sits with the agency, not the reviewers.

    What is the peer review process for grant applications?

    The peer review process for grant applications routes each proposal to subject-matter reviewers, who score it against published criteria and then discuss and rank applications in a panel meeting. Agencies use these rankings to set paylines and prioritise funding. Under OMB’s proposed rule, that ranking becomes one advisory input rather than the determining factor in a funding decision.

    Do grant reviewers get paid?

    Yes. Federal agencies, including NIH, typically pay peer reviewers a daily honorarium plus travel expenses for study section service. Many reviewers describe the compensation as modest relative to the time required to read, score and discuss a full panel’s worth of competing applications ahead of each review cycle.

    Expanded Termination Authority and Award-Level Risk

    Beyond the review gate itself, the proposal reported by STAT, Science and Inside Higher Ed would broaden agencies’ authority to suspend or terminate grants — including multi-year awards already in progress — if they are deemed no longer aligned with agency priorities or the “national interest.” It would also widen risk assessment of applicants to consider an institution’s affiliation with organisations engaged in activities that “violate Federal law, undermine public safety or national security, or advocate for the overthrow of the United States Government,” a standard with considerable interpretive latitude.

    Paired with new pre-approval requirements for publication, conference and journal-subscription costs, and the removal of fixed-amount subawards, the combined effect is a research-funding environment where mid-project risk is materially higher than under the current framework, even for awards that passed scientific review cleanly.

    What This Means for Research Administrators

    For institutions managing portfolios that depend on merit-reviewed research funding, the proposal raises operational, not just scientific, questions. Recommended near-term actions include:

    • Model termination risk explicitly in multi-year budget and staffing plans, rather than treating a scored, funded award as a settled commitment.
    • Audit cost-approval workflows for publication, conference and subscription spending now, ahead of any pre-approval mandate taking effect.
    • Brief principal investigators on the distinction between a favourable peer-review score and a final funding decision under the proposed pre-issuance review.
    • Coordinate institutional comments through professional associations such as NCURA and ARMA before the docket closes.
    • Track subaward structures that rely on fixed-amount mechanisms, which the proposal would eliminate.

    Offices that have historically treated peer-review outcomes as the primary predictor of award stability will need a second, policy-alignment layer in their risk assessment — one that is harder to forecast because it depends on political judgement rather than published scoring criteria.

    What Happens Next

    The proposed rule remains open for public comment, with reporting placing the deadline at 13 July 2026 and a possible effective date of 1 October 2026 if OMB finalises it substantially as drafted. Scientific and higher-education associations are expected to submit extensive comments opposing the advisory reclassification of peer review, and legal challenges are plausible if the rule is finalised without significant revision, given its scope relative to existing statutory peer-review requirements at agencies such as NIH.

    Until the final text is published, research administrators should treat every provision summarised here as subject to change — but the direction of travel is unambiguous: less deference to scientific merit review, and more discretionary authority at the award-decision and award-termination stages. Institutions that update their risk models and compliance workflows now will be better placed to respond once the rule, in whatever form it takes, becomes binding.